Next Article in Journal
Fiducial Markers Allow Accurate and Reproducible Delivery of Liver Stereotactic Body Radiation Therapy
Previous Article in Journal
The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895
 
 
Reply

Article Versions Notes

Curr. Oncol. 2023, 30(5), 5050-5053; https://doi.org/10.3390/curroncol30050381
Action Date Notes Link
article xml file uploaded 16 May 2023 06:01 CEST Original file -
article xml uploaded. 16 May 2023 06:01 CEST Update -
article pdf uploaded. 16 May 2023 06:01 CEST Version of Record -
article html file updated 16 May 2023 06:02 CEST Original file -
article html file updated 16 May 2023 06:02 CEST Update -
article html file updated 16 May 2023 06:03 CEST Update -
article xml file uploaded 16 May 2023 06:11 CEST Update -
article xml uploaded. 16 May 2023 06:11 CEST Update https://www.mdpi.com/1718-7729/30/5/381/xml
article pdf uploaded. 16 May 2023 06:11 CEST Updated version of record https://www.mdpi.com/1718-7729/30/5/381/pdf
article html file updated 16 May 2023 06:12 CEST Update https://www.mdpi.com/1718-7729/30/5/381/html
Back to TopTop